Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—Part 2

S.M. Sagar MD,* D. Yance MH,† and R.K. Wong MD*

ABSTRACT

The herbalist has access to hundreds of years of observational data on the anticancer activity of many herbs. Laboratory studies are expanding the clinical knowledge that is already documented in traditional texts. The herbs that are traditionally used for anticancer treatment and that are anti-angiogenic through multiple interdependent processes (including effects on gene expression, signal processing, and enzyme activities) include Artemisia annua (Chinese wormwood), Viscum album (European mistletoe), Curcuma longa (curcumin), Scutellaria baicalensis (Chinese skullcap), resveratrol and proanthocyanidin (grape seed extract), Magnolia officinalis (Chinese magnolia tree), Camellia sinensis (green tea), Ginkgo biloba, quercetin, Poria cocos, Zingiber officinalis (ginger), Panax ginseng, Rabdosia rubescens hora (Rabdosia), and Chinese destagnation herbs. Natural health products target molecular pathways other than angiogenesis, including epidermal growth factor receptor, the HER2/neu gene, the cyclo-oxygenase-2 enzyme, the nuclear factor kappa-B transcription factor, the protein kinases, the Bcl-2 protein, and coagulation pathways. Quality assurance of appropriate extracts is essential prior to embarking upon clinical trials. More data are required on dose–response, appropriate combinations, and potential toxicities. Given the multiple effects of these agents, their future use for cancer therapy probably lies in synergistic combinations. During active cancer therapy they should generally be evaluated in combination with chemotherapy and radiation. In this role, they act as modifiers of biologic response or as adaptogens, potentially enhancing the efficacy of the conventional therapies or reducing toxicity. Their effectiveness may be increased when multiple agents are used in optimal combinations. New designs for trials to demonstrate activity in human subjects are required. Although controlled trials may be preferable, smaller studies with appropriate endpoints and surrogate markers for anti-angiogenic response could help to prioritize agents for larger, resource-intensive phase III trials.

KEY WORDS

Angiogenesis, anti-angiogenic, natural health products, herbal medicine, anticancer, clinical trials, integrative, molecular biology

1. INTRODUCTION

The biochemical signalling pathways of angiogenesis form a complex, interconnected web. Inhibition of one part of the web may result in compensation through another pathway. Because botanicals contain a variety of organic chemical complexes, they usually act on multiple targets. A potential advantage of phytochemicals is that they may act through multiple pathways and reduce the development of resistance by cancer cells. This model of pharmacognosy recognizes the advantage of administering the whole plant product to maximize activity. Over-extraction of a specific chemical constituent may remove this therapeutic gain. The challenge for modern pharmacognosy is to ensure that the optimum mixture of chemical constituents is maintained when a product is purified. Usually, such assurance will require a combination of chemical and biologic assays.

The additional anticancer properties of some anti-angiogenic botanicals are briefly discussed here. Their properties may affect various biochemical pathways that indirectly influence angiogenesis. Traditional practice has been to combine multiple natural health products, and scientifically, such combination may provide a therapeutic advantage.

2. MULTISTEP ACTIVITY OF PHYTOCHEMICAL COMPLEXES DERIVED FROM HERBS

2.1 Targeting Alternative Angiogenesis Pathways

The adipocytokines—polypeptides produced by adipocytes—have autocrine, paracrine, and endocrine activities, and are associated with obesity, hyperinsulinemia, and chronic vascular disease as
well as with the development of cancer. The adipocytokines include vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), leptin, tumour necrosis factor alpha (TNFα), heparin-binding epidermal growth factor, insulin-like growth factor, and interleukin-6 (IL-6). All can promote angiogenesis.

Curcumin (from turmeric) and epigallocatechin-3 gallate (EGCG, from green tea) can inhibit aminopeptidase-N (CD13), a member of the matrix metalloproteinase family that is implicated in the angiogenic switch process. Curcumin and EGCG can also interfere with the expression of VEGF by suppressing a series of activities that promote angiogenesis. These angiogenic pathways include production of transforming growth factor beta (TGFβ), amplification of cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR), aberrant expression of src, and amplification of nuclear factor kappa-B (NF-κB) signaling. Curcumin, grape seed extract, and green tea constituents may also interfere with endothelial cell function by inhibiting the engagement of specific integrins. These phytochemicals interact at multiple levels to suppress the inflammatory, hyperproliferative and transformative processes that constitute carcinogenesis.

### 2.2 Targeting EGFR (HER1)

In many human tumours, EGFR is overexpressed. Such overexpression is associated with more aggressive disease, relative resistance to cytotoxic chemotherapy, and a poorer prognosis. Activity of EGFR induces angiogenesis. Blockade of EGFR reduces angiogenesis and cell proliferation. Monoclonal antibodies have been developed to block the receptor or the linked intracellular signalling system.

Epidermal growth factor (EGF) stimulates urokinase-type plasminogen activator (uPA) expression, which can promote angiogenesis. Genistein (an isoflavone constituent of soy) and curcumin (a constituent of turmeric) both inhibit the effects of EGF. In cell cultures, genistein and curcumin inhibit EGF-stimulated urokinase production and phosphorylation of EGFR. Both botanicals also inhibit protein tyrosine kinases, which could stimulate the enhancement of uPA levels induced by TGFβ.

Other natural health products that can block activity of EGFR include resveratrol and quercetin.

### 2.3 Targeting HER2/neu

The HER2/neu gene (formerly known as c-erbB-2) is amplified in more than 30% of patients with breast cancer. It is linked to highly aggressive tumours with a poorer prognosis. Overexpression of HER2 is also seen in a significant proportion of patients with other cancer types, including non-small-cell lung cancer, ovarian cancer, prostate cancer, and gastric cancer, in which it may predict a worse outcome. Amplification of the HER2 gene correlates with higher levels of angiogenesis.

Herceptin (Genentech, San Francisco, CA, U.S.A.) is a drug that inhibits HER2/neu. It is usually administered adjunctively with cytotoxic chemotherapy. The activity of Herceptin may be further enhanced by oleic acid. Emodin, a natural constituent of Polygonum multiflorum and aloe, inhibits HER2/neu expression and is toxic against cancer cells, but nontoxic for normal cells.

### 2.4 Targeting Inflammatory Pathways: COX-2 and NF-κB

Prostaglandins are autacoids derived from arachidonic acid via the COX enzymes. They include prostacyclin, thromboxane, and prostaglandin E types 1–3. A role for arachidonic acid–derived prostaglandins in the process of angiogenesis is now established through in vitro assays. Prostaglandin E2 is a potent inducer of angiogenesis. A correlation exists between COX-2 expression and angiogenesis. Neovascularization is blocked by COX-2 antagonists.

The COX-2 and lipoxygenase (LOX-5) products of omega-6 fatty acid metabolism may exert stimulatory effects on cancer progression including angiogenesis. The omega-3 fatty acids and some pharmacologic inhibitors of eicosanoid biosynthesis antagonize these effects. Large amounts of omega-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid] are found in cold-water fish oils. Liquorice contains glycyrrhizic acid and polyphenols that inhibit COX-2, LOX-5, and protein kinase C (PKC) and also downregulate EGFR.

The NF-κB family consists of closely related protein dimers that bind to a common sequence motif in DNA called the κB site. The NF-κB inducible transcription factor is increased in tissue inflammation, cell proliferation, and cancers. Nuclear factor kappa B induces overactivation of the COX enzymes and is associated with increased angiogenesis.

The COX enzymes are expressed in most normal tissues. The COX-1 enzyme synthesizes non-inflammatory prostaglandins such as prostaglandin E1. In contrast, COX-2 is amplified as part of the inflammatory response and produces prostaglandins such as prostaglandin E2, which may induce uncontrolled cell proliferation and carcinogenesis.

Nuclear factor kappa B may be amplified by growth factors, including TGFβ and basic fibroblast growth factor. Besides NF-κB, other transcription factors, such as activator protein-1 (AP-1) and IL-6, can stimulate COX-2 transcription. Activator protein-1 also promotes the metastatic phase of tumour cells.

Angiogenesis mediated by COX-2 also has a role in the progression of pre-neoplastic lesions to the invasive phenotype. Conventional cancer therapies—such as radiation, surgery, and chemotherapy—may
induce COX-2 amplification as part of the inflammatory response. The significance of this induction is unclear, but it could hypothetically reduce therapeutic gain.

Several phytochemical derivatives are potent inhibitors of NF-κB. These include resveratrol, picatannol, curcumin, EGCG, 6-gingerol (ginger), ursolic acid (holy basil), and ginseng. Many botanical COX-2 inhibiting agents block the amplified activity of the transcription factor NF-κB without affecting its normal function.

A variety of natural health products can specifically inhibit the COX-2 enzyme and could play a role in reducing tissue toxicity and improving tumour control when used alongside therapies such as radiotherapy, chemotherapy, and surgery (Table 1). A botanical that protects an organism from the adverse effects of an intervention is termed an adaptogen. Panax ginseng and curcumin are adaptogens that inhibit COX-2 and that have anti-angiogenic activity derived through the inactivation of NF-κB.

### 2.5 Targeting Protein Kinases

Oncogenes that encode protein kinases may contribute to the development of cancer. In normal cells, protein kinases are involved in signals between the cell membrane and the nucleus, regulating progression through the cell cycle. Protein kinases control these processes by activating other messenger proteins that can influence cell proliferation.

Mutated kinase genes have been found in a number of malignancies, including chronic myelogenous leukemia and breast and bladder cancers. The mutated kinases can contribute to the development of cancer. In many tumour cells, protein kinases are permanently turned on, forcing the cell into constant division. Examples of abnormal kinases are the abl, src, and cyclin-dependent kinases. The kinases may be amplified or permanently switched on by mutations in the control regions of their genes. A commonly overproduced kinase in cancer is EGFR.

Numerous phytochemicals are reported to interfere with cell signalling and may reverse the adverse effects of protein kinase overactivity. Some botanicals with COX-2 inhibitory activity target the intracellular signalling molecules. Inhibition of specific protein kinases suppresses angiogenesis.

Carnosol and ursolic acid are compounds found in Ocimum sanctum (holy basil) and Rosmarinus officinalis (rosemary). They inhibit the activity of the tyrosine kinases and ornithine decarboxylase. Carnosol also reduces NF-κB and the anti-apoptotic protein Bcl-2. Genistein and daidzein (isoflavones found in soy) are specific inhibitors of tyrosine kinases.

Many phytochemicals appear to selectively react with the regulatory centre of PKC. Curcumin, vitamin E, green tea (catechins), resveratrol, Ganoderma lucidum, and liquorice can inhibit PKC activity.

### 2.6 Targeting the Bcl-2 Protein

The signalling protein Bcl-2 plays a key role in the process of controlled cell death called apoptosis, which is necessary to eliminate aged or damaged cells. The Bcl-2 protein is normally found in the mitochondrial membrane, where it regulates the release of cytochrome C. The latter protein can trigger a series of enzymes (caspases) that lead to cell death. High Bcl-2 levels are associated with most types of human cancer and block the release of cytochrome C. They appear to be a contributor to both inherent and acquired resistance to anticancer treatments. The BCL2 and TP53 genes regulate VEGF-mediated angiogenesis.

Curcumin and green tea extract inhibit BCL2 expression. Scutellaria baicalensis contains the phenolic compounds baicalin, baicalein, wogonin, and oroxylin. These constituents inhibit BCL2 overexpression, plus COX2 gene expression and NF-κB activation. Hibiscus procatheuic acid is a phenolic compound isolated from the dried flower of Hibiscus sabdariffa L.; it inhibits Bcl-2 activity.

Other inhibitors of Bcl-2 include EPA from fish oil, a lectin extract of Viscum album (mistletoe), 6-gingerol, grape seed extract, echinocystic acid (a triterpene found in ginseng and other Asian herbs), parthenolide (a sesquiterpene lactone found in feverfew), and beta-lapachone (a quinone obtained from the bark of the lapacho tree).

### 2.7 Targeting Coagulation Pathways Associated with Angiogenesis

In some clinical trials, anticoagulation drugs have been associated with a reduction in metastases.
In Chinese medicine, destagnation herbs are traditionally thought to overcome blockages of qi and blood. Laboratory evidence now suggests that these herbs may have anti-angiogenic and anticoagulation properties.103–105 A randomized placebo-controlled trial showed that the addition of “destagnation” herbs (including Salvia miltiorrhiza and Angelica sinensis) to radiotherapy doubled both the local control and the survival rate in patients with nasopharyngeal cancer.

3. CONCLUSION

Angiogenesis involves multiple interdependent processes operating at the molecular level. These include gene expression, signal processing, and enzyme activities. Most anti-angiogenic natural health products block new vessel formation at multiple levels.

Lack of standardization of screening assays may be an obstacle to defining the most effective products for clinical use. Over-extraction of constituents may negate some of the potential synergy. Quality assurance of appropriate extracts is essential before embarking upon clinical trials.

Most studies of anti-angiogenic activity are based on in vitro or animal work that cannot be readily extrapolated to humans. Phase I and II studies are required to determine the potential of these substances to improve cytotoxic therapies. Mainly preclinical data exist for most of the naturally derived anti-angiogenic agents. However, because anti-angiogenic agents are mainly cytostatic in nature, the usual paradigm for anticancer drug development, in which tumour response in phase II trials prompts further development, is not always appropriate. More data are required on dose–response, appropriate combinations, and potential toxicities. Given the multiple effects of these agents, their future use for cancer therapy probably lies in synergistic combinations. They may be evaluated alone for the prevention of cancer recurrence following definitive treatment.

To be suitable for long-term chronic use, these agents should possess minimal toxicity and should be orally administered. However, angiogenesis is also essential for healing of injuries. Most compounds that inhibit tumour angiogenesis are likely to inhibit physiologic angiogenesis, leading to potential side effects such as ulceration and bleeding. Studies are required to determine features that distinguish tumour vessels from normal vessels so that a therapeutic gain can be achieved. Some of the differences have already been described, but the doses and scheduling of anti-angiogenic agents appropriate to achieving the optimum therapeutic gain are unclear.

During active cancer therapy anti-angiogenic agents should generally be evaluated in combination with chemotherapy and radiation. In that role, they act as modifiers of the biologic response and as adaptogens, potentially enhancing the efficacy and reducing toxicity of conventional therapies. The combination of diversity in angiogenic factor expression and different phenotypes of endothelial cells within various tumours is a major challenge for the development of effective anti-angiogenic regimens.107,108 Effectiveness may be increased when multiple agents are used in optimal combinations.

Surrogate markers, such as angiogenic cytokines, are necessary to predict anti-angiogenic response.109 Circulating levels of fibroblast growth factor–2, VEGF, vascular cell adhesion molecule–1, endothelial intercellular adhesion molecule–1, insulin-like growth factor–1, and cytokines such as interleukin-8 may correlate with tumour angiogenesis.110–114 In addition, circulating endothelial cells and their progenitors may be a more reliable marker of response to anti-angiogenic therapies.115,116 Non-invasive functional imaging, such as positron emission tomography and functional magnetic resonance imaging, may play a role.

Current laboratory evidence suggests a useful role for natural health products in the treatment of cancer. The input of an herbalist, an oncologist, a laboratory scientist, and a clinical trials methodologist to the research effort is essential to distil the wealth of traditional knowledge into a modern framework that can be evaluated scientifically. Information on traditional dose levels is important for designing initial phase I clinical trials for safety and maximum tolerated dose (Table II). However, the traditional model of pharmacognosy may not necessarily use the highest dose. Establishing the maximum tolerated dose in a phase I study may not always be appropriate. Instead, determination of the biologically active dose that may possess less toxicity may be more relevant. Combinations of whole herbs or constituent phytochemicals at lower doses may be important. In addition, a longer period of exposure to the natural health product may be more effective than a short exposure to the highest possible dose level. New designs for trials to demonstrate activity in human subjects are required.

Although controlled trials might be preferred, smaller studies with appropriate endpoints and surrogate markers for anti-angiogenic response could help to prioritize agents for the larger, resource-intensive phase III trials. Because most of the agents are expected to be cytostatic, it is inappropriate to require the standard criteria of measured tumour response. On the other hand, simply confirming stable disease may be misleading. More research on surrogate markers of anti-angiogenic response is obviously necessary before resources can be directed to large-scale clinical trials (Table III).

The further development of natural health products for clinical trials will require a team effort between academic centres, government, and industry. Appropriate financial support and market protection will be necessary to encourage this activity. New ways of supporting evidence-based innovation for natural
health products are necessary, without necessarily separating and isolating all the constituents of a natural health product simply to allow patent registration. Commercial protection for companies that provide quality assurance and clinical trials evidence may be necessary. Another model includes government support for evaluation, with some profit being returned to the government when a product is commercialized. Part of the funding for clinical studies of the AE-941 shark cartilage derivative (Neovastat: Æterna Zentaris, Quebec, QC, Canada) came from Technology Partnerships Canada, a research support program of the federal government of Canada.

Teamwork between the oncologist, the herbalist, the laboratory scientist, and the research methodologist is important for studying anti-angiogenic herbs and other natural health products. As clinical trials introduce these products into the clinic, more definitive evidence of efficacy will be provided and more cancer patients may potentially experience improved outcomes.

4. REFERENCES

1. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004;5:153–65.

2. Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 2003;10:695–704.

3. Tang FY, Nguyen N, Meydani M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VEGF-mediated endothelial cell proliferation and inactivation of Akt protein. Int J Cancer 2003;106:871–8.

4. Kojima–Yuasa A, Hua JJ, Kennedy DO, Matsui–Yuasa I. Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors. Life Sci 2003;73:1299–313.

5. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 2004;108:733–40.

6. Khanna S, Roy S, Bagchi D, Bagchi M, Sen CK. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 2001;31:38–48.

7. Casanova ML, Larcher F, Casanova B, et al. A critical role for ras-mediated epidermal growth factor receptor–dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002;62:3402–7.

8. Wu JL, Abe T, Inoue R, Fujiki M, Kobayashi H. mBoM suppresses angiogenesis and tumorogenesis promoted by an antiangiogenic agent. J Biol Chem 2004;279:785–91.

9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.

10. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(suppl 4):S9–15.

11. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983;80:1337–41.

12. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002–7.

13. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato...
19. Banerjee T, Van der Vliet A, Ziboh V A. Down regulation of

20. Huynh H, Nguyen TT, Chan E, Tran E. Inhibition of

21. Ma ZS, Huynh TH, Ng CP , Do PT, Nguyen TH, Huynh H.

22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, 

23. Slamon DJ, Leyland–Jones B, Shak S, et al. Use of chemo-

24. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-acti-

25. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene

26. Menendez JA, Vellon L, Colomer R, Lupu R, Oleic acid, the

27. Blackwell KL, Dewhirst MW, Liotcheva V, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003:9: 2651–6.

28. Menendez JA, Vellon L, Colomer R, Lupu R, Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses HER-2/neu (ErbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with HER-2/neu oncogene amplification. Ann Oncol 2005;16:359–71.

29. Wasserman L, Avigad S, Beery E, Nordenberg J, Fenig E. The effect of aloe emodin on the proliferation of a new Merkel carcinoma cell line. Am J Dermatopathol 2002;24:17–22.

30. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003:9: 2651–6.

31. Ben Ezra D. Neovascularogenic ability of prostaglandins, growth factors and synthetic chemoattractants. Am J Ophthalmol 1978; 86:455–61.

32. Ziche M, Jones J, Gulino PM. Role of prostaglandin E1 and copper in angiogenesis. J Nat Cancer Inst 1982;69:475–82.

33. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214–18.

34. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31(suppl 7):2–11.

35. Ruegg C, Dormond O, Mariotti A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 2004;1654:51–67.

36. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179–92.

37. Connolly JM, Liu XH, Rose DP. Dietary linoleic acid–stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer 1996;25:231–40.

38. Rose DP, Connolly JM, Coleman M. Effect of N-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin Cancer Res 1996;2:1751–6.

39. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999;83:217–44.

40. Connolly JM, Liu XH, Rose DP. Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice. Nutr Cancer 1997; 29:48–54.

41. Larsson SC, Kumlin M, Ingelman–Sundberg M, Wolk A. Dietary long-chain N-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79: 935–45.

42. Wang ZY, Nixon DW. Loricice and cancer. Nutr Cancer 2001; 39:1–11.

43. Shibata A, Nagaia T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237–43.

44. Yu HG, Zhong X, Yang YN, et al. Increased expression of nuclear factor-kB/RelA is correlated with tumor angiogenesis in human colorectal cancer. Int J Colorectal Dis 2004;19: 18–22.

45. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419–28.

46. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)–2 inhibitor celecoxib abrogates TNF-induced NF-kB activation
through inhibition of activation of IκB α kinase and akt in human non-small cell lung carcinoma: correlation with suppression of cox-2 synthesis. J Immunol 2004;173:2011–22.

47. Guinebretiere JM, Le Monique G, Gavioille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Nat Cancer Inst 1994;86:635–6.

48. Fregene TA, Kellogg CM, Pienta KJ. MicrovesSEL quantification as a measure of angiogenic activity in benign breast tissue lesions: marker for precancerous disease? Int J Oncol 1994;4:1199–2002.

49. Heffelfinger SC, Yassin R, Miller MA, Lower E. Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. Clin Cancer Res 1996;2:1873–8.

50. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678–87.

51. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for chemoprevention and treatment. Trends Pharmacol Sci 2003;24:96–102.

52. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target for angiogenesis. Trends Mol Med 2003;9:73–8.

53. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclooxygenase-2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999;18:6013–20.

54. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998;273:21875–82.

55. Oh GS, Pae HO, Choi BM, et al. Inhibitors of cyclooxygenase and lipoxygenase expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett 2004;205:23–9.

56. Bode AM, Ma WY, Surh YJ, Dong Z. Inhibition of epidermal growth factor induced cell transformation and AP1 activation by [6]-gingerol. Cancer Res 2001;61:850–3.

57. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade: eicosanoids, cyclooxygenases, and lipoxygenases as an adjunct in cancer therapy. Integr Cancer Ther 2002;1:7–37.

58. Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, NF-κB, and AP-1, and NF-κB. Arterioscler Thromb Vasc Biol 1997;17:3406–13.

59. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitor protein IκB kinase activity. J Immunol 1999;163:3474–83.

60. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBzeta kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053–62.

61. Siwak DR, Shishodita S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the akt pathway. Cancer 2003;104:879–90.

62. Surh YJ, Na HK, Lee SS. Transcription factors and mitogen-activated protein kinases as molecular targets for chemoprevention with anti-inflammatory phytochemicals. Biofactors 2004;21:103–8.

63. Huang P, Olliff A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol 2001;11:343–8.

64. Roberts WG, Whalen PM, Soderstrom E, et al. Antiangiogenic and antitumor activity of a selective PDGF tyrosine kinase inhibitor, CP-673, 451. Cancer 2005;65:957–66.

65. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000;97:1749–53.

66. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003;93:321–9.

67. Haspel HC, Scicli GM, McMahon G, Scicli AG. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Microvasc Res 2002;63:304–15.

68. Bold G, Altmann KH, Frei J, et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 2000;43:2310–20.

69. Wang Y, Wei X, Xiao X, et al. Arachidonic acid epoxyeicosatriene metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/akt signaling pathways. J Pharmacol Exp Ther 2005;314:522–32.

70. Lauthier F, Taillet L, Trouillas P, Delage C, Simon A. Ursolic acid triggers calcium-dependent apoptosis in human Daudi cells. Anticancer Drugs 2000;11:737–45.

71. Danilenko M, Wang X, Studzinski GP. Carnosic acid and resveratrol inhibit cyclooxygenase-2 and downregulation of Bcl-2 in B-lineage leukemia cells. Cancer Res 2001;61:3024–33.

72. Plouzek CA, Ciolino HP, Clarke R, Yeh GC. Inhibition of P-glycoprotein activity and reversal of multidrug resistance by curcumin. J Natl Cancer Inst 2001;93:1224–33.

73. Sachinidis A, Hescheler J. Are catechins natural tyrosine kinase inhibitors? Drug News Perspect 2002;15:432–8.

74. Lin YL, Liang YC, Lee SS, Chiang BL. Polysaccharide purification from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-κB and p38 mitogen-activated protein kinase pathways. J Leukoc Biol 2005;78:533–43.
86. Chen Y, Yang L, Lee TJ. Oroxylin A inhibition of lipopolysaccharide-induced nuclear factor-κB (NF-κB) activation. Cell Biol Toxicol 2003;19:147–57.
87. Tseng TH, Hsu JD, Lo MH, et al. Induction of apoptosis and telomerase inhibition in human A253 cancer cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. J Natl Cancer Inst 20:26:1017–23.
88. Lee JH, Cheong J, Park YM, Choi YH. Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells. Pharmacol Res 2005;51:553–60.
89. Park DI, Lee JH, Moon SK, et al. Induction of apoptosis and inhibition of telomerase activity by aqueous extract from Platyodon grandiflorum in human lung carcinoma cells. Pharmacol Res 2005;51:437–43.
90. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999;91:22–36.
91. Sweeney CJ, Miller KDA, Sledge GW Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003:9:24–9.
92. Ria R, Portaluri M, Russo F, et al. In vivo role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev 2000:19:147–57.
93. Sweeney CJ, Miller KDA, Sledge GW Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003:9:24–9.
94. Wong CC, Chen LG, Lee LT, Yang LL. Effects of 6-gingerol, an antioxidant from ginger, on inducing apoptosis in human leukemic HL-60 cells. In vivo 2003;17:641–5.
95. Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 2000;148:187–97.
96. Yu Y, Yang L, Yu M, et al. Inhibition of angiogenesis activity of Chinese medicinal herbal extracts. Life Sci 2004;74:2467–78.
97. Smorenburg SM, Van Noorden CJ. The complex effects of heparin on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53:93–105.
98. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–22.
99. Wang S, Zheng Z, Weng Y, et al. Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts. J Natl Cancer Inst 2004;216:103–7.
95:1425–7.
113. Ruegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and antiangiogenesis trials. Curr Mol Med 2003;3:673–91.
114. Salcedo X, Medina J, Sanz–Cameno P, Garcia–Buey L, Martin–Vilchez S, Moreno–Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005;22:23–30.
115. Schneider M, Tjwa M, Carmeliet P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005;7:3–4.
116. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101–11.

117. Neeman M. Preclinical MRI experience in imaging angiogenesis. Cancer Metastasis Rev 2000;19:39–43.
118. AE 941. Drugs R D 2004;5:83–9.

Corresponding author: Stephen M. Sagar, Juravinski Cancer Centre and McMaster University (Department of Medicine), 699 Concession Street, Hamilton, Ontario L8V 5C2.
E-mail: stephen.sagar@hrcc.on.ca

* Juravinski Cancer Centre and McMaster University (Department of Medicine), Hamilton, Ontario.
† Center for Natural Healing, Ashland, Oregon, U.S.A.